To the Editor: There has been debate on the association between sulfonylureas and cardiovascular mortality, and in his letter in Diabetologia, J. A. Tayek describes studies that demonstrate an increased risk of mortality in type 2 diabetic patients treated with sulfonylureas [1] . He rightly highlights that Evans et al. [2] demonstrated an increase in cardiovascular mortality with sulfonylurea monotherapy compared with metformin monotherapy. However, it must be pointed out that the reported data are from an observational, retrospective study that used data resources of the Diabetes Audit and Research in Tayside, Scotland (DARTS)/the Medicines Monitoring Unit (MEMO) Collaboration. Consequently, there was no control group for identification of underlying differences between groups. Furthermore, patients in the sulfonylurea cohort had a higher baseline cardiovascular risk, as this group had an increased mean age and duration of diabetes and a higher proportion of men and patients with previous cardiovascular hospital admissions, all of which may have contributed to the excess mortality observed in this group. Moreover, the results of this study are difficult to interpret and raise the question: Are sulfonylureas cardiotoxic or is metformin cardioprotective?
Tayek points out that it would be helpful to know whether different sulfonylureas were used in the study Evans et al., and, if so, whether there were any differences in mortality between them. We questioned J. M. M. Evans about the nature of the sulfonylureas used in the study. She pointed out that, although it is difficult to specify in what proportion each sulfonylurea was prescribed, of the 2,079 patients who were first treated with a sulfonylurea, only 157 (7.5%) were treated with one of the older sulfonylureas such as glibenclamide (known as glyburide in the USA and Canada).
In the second study discussed, Tayek makes reference to the University Group Diabetes Program (UGDP) trial [3] . Although tolbutamide monotherapy was associated with an increase in cardiovascular mortality, this was restricted to a small group of patients with poorly controlled diabetes. The results of this study have been largely rejected by the diabetic community because of problems associated with the trial design in terms of inadequate patient selection and compliance to therapy.
Tayek also makes reference to the study by Simpson and co-workers [4] , which also showed a higher risk of mortality with the use of sulfonylureas. Again, this was a retrospective study based on administrative data from Saskatchewan Health. Although an increase in mortality is reported in the sulfonylurea group, the results are difficult to interpret. First, the study was observational and retrospective based on databases; thus, differences in underlying cardiovascular risks may justify differential mortality rates. Second, the measure of drug exposure is limited as drug acquirement was used as a marker of consumption; thus, the study may have overestimated actual drug use. The study also demonstrated that compared with lower doses, high doses of sulfonylureas were associated with increased rates of death. This finding is difficult to interpret as patients given higher doses of oral glucose-lowering therapies may have presented with worse glycaemia and/or more advanced type 2 diabetes, which are confounding factors. The same group of investigators demonstrated in another two studies [5, 6] using the same database that, compared with sulfonylurea monotherapy, the combination of sulfonylurea and metformin is associated with a reduced risk of mortality. These findings are in contrast to those reported by Olsson and co-workers [7] , also referred to by Tayek in his letter [1] . Although Olsson and colleagues reported that mortality was increased in diabetic patients given a combination of sulfonylurea and metformin compared with those patients given sulfonylurea alone, this study involved far fewer patients than the study by Johnson et al. [6] . Moreover, Olsson et al. [7] state that the observed increased mortality in the combination group may be secondary to a more aggressive type of diabetes. This again highlights the difficulty involved in interpreting observational studies lacking corresponding control groups.
In the UKPDS [8] , when glycaemic control was not achieved in a group of patients, despite maximal sulfonylurea doses, add-on therapy with metformin was given. Surprisingly, the addition of metformin therapy was associated with an increase in mortality. This finding has, however, been justified. First, those patients given metformin in addition to sulfonylureas had a more severe baseline hyperglycaemia compared with those on monotherapy, and thus were already at an increased risk of death. Second, there were fewer deaths than expected in the sulfonylurea monotherapy group. In addition, the UKPDS demonstrated that 11 years of treatment with glibenclamide not only controlled glycaemia, but also significantly reduced the incidence of microvascular complications. In fact, a trend towards a reduction in the risk of macrovascular complications was observed in the glibenclamide cohort, although this did not reach statistical significance. Likewise, no evidence of an adverse effect on cardiovascular outcomes was reported with chlorpropamide in the UKPDS [8] .
Finally, in the recently published A Diabetes Outcome Progression Trial (ADOPT) [9] , glibenclamide was associated with a lower risk of serious cardiovascular events than either rosiglitazone or metformin.
Sulfonylureas are a key treatment option for type 2 diabetes. This is highlighted by their clinical efficacy and endorsement by various clinical guidelines, including recent International Diabetes Federation guidelines [10] . Studies demonstrating excess mortality with sulfonylureas were retrospective, observational trials, which were not designed to evaluate the potential risks afforded by sulfonylureas on cardiovascular mortality in diabetic patients. Investigators of these studies themselves acknowledge and highlight the flaws of their respective studies as a result of confounding variables and the lack of matching control groups. The results of such studies are therefore difficult to interpret and merely fuel controversy. Appropriately designed, prospective, randomised, placebo-controlled clinical trials are required to fully establish whether sulfonylureas are truly linked to excess cardiovascular mortality. To date, only three prospective, randomised studies have provided information on the use of sulfonylureas and associated cardiovascular events in type 2 diabetic patients-the poorly designed UGDP study [3] , and the UKPDS [8] and ADOPT [9] studies, which both found no increased cardiovascular events with the use of sulfonylureas.
Ultimately, the future of sulfonylureas does not depend on cardiovascular risk, but on the effectiveness of glucagon-like peptide-1 analogues and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. The efficacy and benefits of these new drugs need to be evaluated vs sulfonylureas in long-term studies.
